Skip to content

Study · Randomized controlled trial · n = 160 · 1996

8 results

Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group.

Fernandez del Moral P, Dijkman GA, Debruyne FM, Witjes WP, Kolvenbag GJ

Urology1 Dec 1996Cited by 15 (Europe PMC)

PMID8973673 (opens in a new tab)DOI10.1016/s0090-4295(96)00300-7 (opens in a new tab)PepBankPUB-08973673
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialActivity measurement

    In advanced prostate cancer, testosterone profiles were similar with 10.8-mg and 3.6-mg goserelin depots.

    In plain wordsThe two goserelin depots produced similar testosterone profiles in advanced prostate cancer.

    Peptide
    Goserelin
    Outcome
    Direction not reportedSerum testosterone profile
    Study

    n = 160

    Comparator
    3.6 mg goserelin every 4 weeks
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    10.8 mg every 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Serum testosterone profiles of the 10.8-mg goserelin acetate depot and the 3.6-mg goserelin acetate depot were similar; testosterone levels in both groups fell below castrate levels by day 21 after administration.
    3 context sentences
    Summary · context
    To compare the pharmacodynamics and tolerability of the new goserelin acetate 10.8-mg depot with the 3.6-mg depot in patients with advanced prostate cancer during the first 3 months of therapy.
    Summary · context
    One hundred sixty patients were randomized in two comparative studies to receive either the 10.8-mg goserelin acetate depot every 12 weeks or the 3.6-mg goserelin acetate depot every 4 weeks for 12 weeks and then the 10.8-mg depot every 12 weeks thereafter.
    Summary · context
    Data for pharmacodynamic assessments were collected prospectively, whereas clinical response data were collected retrospectively.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In advanced prostate cancer, PSA decreases were similar at 3 months, 94% with 10.8-mg versus 92.5% with 3.6-mg goserelin.

    In plain wordsPSA decreased similarly with both goserelin depots in advanced prostate cancer.

    Peptide
    Goserelin
    Outcome
    Direction not reportedProstate-specific antigen reduction
    Study

    n = 160

    Comparator
    3.6 mg goserelin every 4 weeks
    Outcome group
    Tumor growth · Cancer
    Studied dose
    10.8 mg every 12 weeks · 3 monthsAs given in this study (human).

    Measurements

    PSA decrease
    94%
    10.8-mg depot, 3 months
    PSA decrease
    92.5%
    3.6-mg depot, 3 months

    Source sentences

    Summary
    Decreases in serum prostate-specific antigen level after 3 months of therapy were also similar in both groups: 94% with the 10.8-mg depot and 92.5% with the 3.6-mg depot.
    3 context sentences
    Summary · context
    To compare the pharmacodynamics and tolerability of the new goserelin acetate 10.8-mg depot with the 3.6-mg depot in patients with advanced prostate cancer during the first 3 months of therapy.
    Summary · context
    One hundred sixty patients were randomized in two comparative studies to receive either the 10.8-mg goserelin acetate depot every 12 weeks or the 3.6-mg goserelin acetate depot every 4 weeks for 12 weeks and then the 10.8-mg depot every 12 weeks thereafter.
    Summary · context
    Data for pharmacodynamic assessments were collected prospectively, whereas clinical response data were collected retrospectively.
  3. 03HumanRandomized controlled trialSafety outcome

    In advanced prostate cancer, the safety profile of 10.8-mg goserelin was similar to the 3.6-mg depot.

    In plain wordsThe two goserelin depots had similar safety profiles in advanced prostate cancer.

    Peptide
    Goserelin
    Outcome
    Direction not reportedSafety profile
    Study

    n = 160

    Comparator
    3.6 mg goserelin every 4 weeks
    Outcome group
    Adverse events · Whole body
    Studied dose
    10.8 mg every 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The safety profile of the 10.8-mg goserelin acetate depot was similar to that of the 3.6-mg depot; hot flashes was the most common adverse event.
    3 context sentences
    Summary · context
    To compare the pharmacodynamics and tolerability of the new goserelin acetate 10.8-mg depot with the 3.6-mg depot in patients with advanced prostate cancer during the first 3 months of therapy.
    Summary · context
    One hundred sixty patients were randomized in two comparative studies to receive either the 10.8-mg goserelin acetate depot every 12 weeks or the 3.6-mg goserelin acetate depot every 4 weeks for 12 weeks and then the 10.8-mg depot every 12 weeks thereafter.
    Summary · context
    Data for pharmacodynamic assessments were collected prospectively, whereas clinical response data were collected retrospectively.
  4. 04HumanNon-randomized trialActivity measurement

    In advanced prostate cancer, both goserelin depots reduced testosterone below castrate levels by day 21.

    In plain wordsBoth goserelin depots reduced testosterone below castrate levels by day 21 in advanced prostate cancer.

    Peptide
    Goserelin
    Outcome
    DecreaseTestosterone suppression
    Study

    n = 160

    Comparator
    Before administration
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    10.8 mg every 12 weeks or 3.6 mg every 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Serum testosterone profiles of the 10.8-mg goserelin acetate depot and the 3.6-mg goserelin acetate depot were similar; testosterone levels in both groups fell below castrate levels by day 21 after administration.
    3 context sentences
    Summary · context
    To compare the pharmacodynamics and tolerability of the new goserelin acetate 10.8-mg depot with the 3.6-mg depot in patients with advanced prostate cancer during the first 3 months of therapy.
    Summary · context
    One hundred sixty patients were randomized in two comparative studies to receive either the 10.8-mg goserelin acetate depot every 12 weeks or the 3.6-mg goserelin acetate depot every 4 weeks for 12 weeks and then the 10.8-mg depot every 12 weeks thereafter.
    Summary · context
    Data for pharmacodynamic assessments were collected prospectively, whereas clinical response data were collected retrospectively.
  5. 05HumanNon-randomized trialSafety outcome

    In advanced prostate cancer patients receiving goserelin, hot flashes were the most common adverse event.

    In plain wordsHot flashes were the most common adverse event in advanced prostate cancer patients receiving goserelin.

    Peptide
    Goserelin
    Outcome
    Not applicableHot flashes
    Study

    n = 160

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The safety profile of the 10.8-mg goserelin acetate depot was similar to that of the 3.6-mg depot; hot flashes was the most common adverse event.
    3 context sentences
    Summary · context
    To compare the pharmacodynamics and tolerability of the new goserelin acetate 10.8-mg depot with the 3.6-mg depot in patients with advanced prostate cancer during the first 3 months of therapy.
    Summary · context
    One hundred sixty patients were randomized in two comparative studies to receive either the 10.8-mg goserelin acetate depot every 12 weeks or the 3.6-mg goserelin acetate depot every 4 weeks for 12 weeks and then the 10.8-mg depot every 12 weeks thereafter.
    Summary · context
    Data for pharmacodynamic assessments were collected prospectively, whereas clinical response data were collected retrospectively.
  6. 06HumanNon-randomized trialSafety outcome

    In advanced prostate cancer, injection site reactions occurred after 2 of 614 goserelin administrations, reported as 0.3%.

    In plain wordsInjection site reactions occurred after 2 of 614 goserelin administrations in advanced prostate cancer.

    Peptide
    Goserelin
    Outcome
    Not applicableInjection site reactions
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated

    Measurements

    Injection site reactions
    2 reactions
    of 614 administrations
    Administrations
    614 administrations
    denominator
    Injection site reaction incidence
    0.3%
    per administration

    Source sentences

    Summary
    The incidence of injection site reactions was very low (2 [0.3%] of 614 administrations).
    3 context sentences
    Summary · context
    To compare the pharmacodynamics and tolerability of the new goserelin acetate 10.8-mg depot with the 3.6-mg depot in patients with advanced prostate cancer during the first 3 months of therapy.
    Summary · context
    One hundred sixty patients were randomized in two comparative studies to receive either the 10.8-mg goserelin acetate depot every 12 weeks or the 3.6-mg goserelin acetate depot every 4 weeks for 12 weeks and then the 10.8-mg depot every 12 weeks thereafter.
    Summary · context
    Data for pharmacodynamic assessments were collected prospectively, whereas clinical response data were collected retrospectively.
  7. 07HumanObservational studyEfficacy outcome

    In advanced prostate cancer patients receiving goserelin, median time to progression was 152.7 weeks.

    In plain wordsMedian time to progression was 152.7 weeks in advanced prostate cancer patients receiving goserelin.

    Peptide
    Goserelin
    Outcome
    Not applicableMedian time to progression
    Study

    n = 160

    Outcome group
    Tumor growth · Cancer
    Studied dose
    10.8-mg or 3.6-mg depot, then 10.8-mg depotAs given in this study (human).

    Measurements

    Median time to progression
    152.7 weeks
    all patients

    Source sentences

    Summary
    For all patients, the median time to progression was 152.7 weeks and the median time to death was 213.6 weeks.
    3 context sentences
    Summary · context
    To compare the pharmacodynamics and tolerability of the new goserelin acetate 10.8-mg depot with the 3.6-mg depot in patients with advanced prostate cancer during the first 3 months of therapy.
    Summary · context
    One hundred sixty patients were randomized in two comparative studies to receive either the 10.8-mg goserelin acetate depot every 12 weeks or the 3.6-mg goserelin acetate depot every 4 weeks for 12 weeks and then the 10.8-mg depot every 12 weeks thereafter.
    Summary · context
    Data for pharmacodynamic assessments were collected prospectively, whereas clinical response data were collected retrospectively.
  8. 08HumanObservational studyEfficacy outcome

    In advanced prostate cancer patients receiving goserelin, median time to death was 213.6 weeks.

    In plain wordsMedian time to death was 213.6 weeks in advanced prostate cancer patients receiving goserelin.

    Peptide
    Goserelin
    Outcome
    Not applicableMedian time to death
    Study

    n = 160

    Outcome group
    Mortality · Cancer
    Studied dose
    10.8-mg or 3.6-mg depot, then 10.8-mg depotAs given in this study (human).

    Measurements

    Median time to death
    213.6 weeks
    all patients

    Source sentences

    Summary
    For all patients, the median time to progression was 152.7 weeks and the median time to death was 213.6 weeks.
    3 context sentences
    Summary · context
    To compare the pharmacodynamics and tolerability of the new goserelin acetate 10.8-mg depot with the 3.6-mg depot in patients with advanced prostate cancer during the first 3 months of therapy.
    Summary · context
    One hundred sixty patients were randomized in two comparative studies to receive either the 10.8-mg goserelin acetate depot every 12 weeks or the 3.6-mg goserelin acetate depot every 4 weeks for 12 weeks and then the 10.8-mg depot every 12 weeks thereafter.
    Summary · context
    Data for pharmacodynamic assessments were collected prospectively, whereas clinical response data were collected retrospectively.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.